AT 466
Alternative Names: AT-466Latest Information Update: 29 Aug 2023
Price :
$50 *
At a glance
- Originator Audentes Therapeutics
- Developer Astellas Gene Therapies
- Class Antisense oligonucleotides
- Mechanism of Action Myotonin protein kinase expression inhibitors; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Myotonic dystrophy
Most Recent Events
- 29 Aug 2023 AT 466 is still in research phase for Myotonic dystrophy in USA (Astellas Gene Therapies pipeline; August 2023)
- 29 Aug 2023 Early research in Myotonic dystrophy in USA (Parenteral) (Astellas Gene Therapies pipeline; August 2023)
- 28 May 2023 No recent reports of development identified for preclinical development in Myotonic dystrophy in USA (Parenteral)